Literature DB >> 9146845

The need for large-scale randomized evidence.

C Baigent1.   

Abstract

The reliable detection of moderate differences in major health outcomes that arise as a result of treatment requires large-scale randomized evidence (and the appropriate interpretation of this evidence once it has been generated). This may take the form of a single mega-trial or, exceptionally, a meta-analysis of many smaller randomized trials may provide worthwhile information. Small or non-randomized studies cannot generally be trusted to distinguish reliably between a moderate benefit, a moderate hazard, and a negligible difference in major outcomes. Simple design, streamlined data collection, and use of the "uncertainty principle' to guide eligibility would all encourage the recruitment of larger samples in randomized trials. Future trials need to adopt these methods in order to detect any moderate improvements in major outcomes that may await discovery.

Mesh:

Year:  1997        PMID: 9146845      PMCID: PMC2042762          DOI: 10.1046/j.1365-2125.1997.00569.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  Why randomized controlled trials fail but needn't: 2. Failure to employ physiological statistics, or the only formula a clinician-trialist is ever likely to need (or understand!).

Authors:  D L Sackett
Journal:  CMAJ       Date:  2001-10-30       Impact factor: 8.262

2.  What have we learned about trial design from NIMH-funded pragmatic trials?

Authors:  John March; Helena C Kraemer; Madhukar Trivedi; John Csernansky; John Davis; Terence A Ketter; Ira D Glick
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

Review 3.  Randomized controlled trials and neuro-oncology: should alternative designs be considered?

Authors:  Alireza Mansouri; Samuel Shin; Benjamin Cooper; Archita Srivastava; Mohit Bhandari; Douglas Kondziolka
Journal:  J Neurooncol       Date:  2015-08-22       Impact factor: 4.130

4.  Clinical diagnosis of lacunar stroke in the first 6 hours after symptom onset: analysis of data from the glycine antagonist in neuroprotection (GAIN) Americas trial.

Authors:  Stephen J Phillips; Dingwei Dai; Arnold Mitnitski; Gordon J Gubitz; Karen C Johnston; Walter J Koroshetz; Karen L Furie; Sandra Black; Darell E Heiselman
Journal:  Stroke       Date:  2007-08-23       Impact factor: 7.914

5.  Considerations for a surgical RCT for diffuse low-grade glioma: a survey.

Authors:  Alireza Mansouri; Karanbir Brar; Michael D Cusimano
Journal:  Neurooncol Pract       Date:  2019-11-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.